AAAAAA

   
Results: 1-12 |
Results: 12
Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine
Authors: Ring, BJ Eckstein, JA Gillespie, JS Binkley, SN Vandenbranden, M Wrighton, SA
Citation: Bj. Ring et al., Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine, J PHARM EXP, 297(3), 2001, pp. 1044-1050
Present and future in vitro approaches for drug metabolism
Authors: Ekins, S Ring, BJ Grace, J McRobie-Belle, DJ Wrighton, SA
Citation: S. Ekins et al., Present and future in vitro approaches for drug metabolism, J PHARM TOX, 44(1), 2000, pp. 313-324
Inversion of real time spot prices in the direction of real power flow in a transmission line
Authors: Ward, AG Watson, NR Arnold, CP Turner, AJ Ring, BJ
Citation: Ag. Ward et al., Inversion of real time spot prices in the direction of real power flow in a transmission line, IEEE POW SY, 15(4), 2000, pp. 1197-1203
A population approach to enzyme characterization and identification: Application to phenacetin O-deethylation
Authors: Belle, DJ Ring, BJ Allerheiligen, SRB Heathman, MA O'Brien, LM Sinha, V Roskos, LK Wrighton, SA
Citation: Dj. Belle et al., A population approach to enzyme characterization and identification: Application to phenacetin O-deethylation, PHARM RES, 17(12), 2000, pp. 1531-1536
Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors, DRUG META D, 28(8), 2000, pp. 994-1002
Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium
Authors: Ekins, S Ring, BJ Bravi, G Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium, IUL BIOTECH, 2, 2000, pp. 269-299
Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors, PHARMACOGEN, 9(4), 1999, pp. 477-489
Predicting drug interactions and pharmacokinetic variability with in vitromethods: The olanzapine experience
Authors: Wrighton, SA Ring, BJ
Citation: Sa. Wrighton et Bj. Ring, Predicting drug interactions and pharmacokinetic variability with in vitromethods: The olanzapine experience, DRUG METAB, 31(1), 1999, pp. 15-28
Flavin-containing monooxygenase-mediated N-oxidation of the M-1-muscarinicagonist xanomeline
Authors: Ring, BJ Wrighton, SA Aldridge, SLK Hansen, K Haehner, B Shipley, LA
Citation: Bj. Ring et al., Flavin-containing monooxygenase-mediated N-oxidation of the M-1-muscarinicagonist xanomeline, DRUG META D, 27(10), 1999, pp. 1099-1103
Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors
Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors, J PHARM EXP, 290(1), 1999, pp. 429-438
Three-dimensional quantitative structure activity relationship analyses ofsubstrates for CYP2B6
Authors: Ekins, S Bravi, G Ring, BJ Gillespie, TA Gillespie, JS Vandenbranden, M Wrighton, SA Wikel, JH
Citation: S. Ekins et al., Three-dimensional quantitative structure activity relationship analyses ofsubstrates for CYP2B6, J PHARM EXP, 288(1), 1999, pp. 21-29
Autoactivation and activation of the cytochrome P450s
Authors: Ekins, S Ring, BJ Binkley, SN Hall, SD Wrighton, SA
Citation: S. Ekins et al., Autoactivation and activation of the cytochrome P450s, INT J CL PH, 36(12), 1998, pp. 642-651
Risultati: 1-12 |